Yükleniyor... / Loading...
This study examines neoadjuvant (pre-surgery) chemotherapy (Oxaliplatin, Capecitabine, and Panitumumab in some patients) in patients with locally advanced colon cancer. It enrolled patients aged 18 or older with histologically confirmed T3 or T4 colon cancer whose tumors were analyzed for KRAS, BRAF, and PIK3CA. The study was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan * Analysis of KRAS, BRAF, PIK3CA * Age ≥18 år * Performance status ≤ 2 * Hematology * ANC ≥ 1.5x10\^9/l. Thrombocytes ≥ 100x10\^9/l. * Biochemistry * Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL * Consent to translational research * Fertile women must present a negative pregnancy test and use secure birth control during and 3 months after treatment. * Written and orally informed consent. Exclusion Criteria: * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent disease. * Peripheral neuropathy NCI grade \>1 * Other malignant disease within 5 years prior to enrollment, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ * Other investigational treatment within 30 days prior to treatment start * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. * Bleeding tumors * Hypersensitivity to one or more of the substances